IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
Jon M. Wigginton(Bristol-Myers Squibb (United States)), Robert H. Wiltrout(Frederick National Laboratory for Cancer Research), Lisa Geiselhart(Frederick National Laboratory for Cancer Research), Kunio Nagashima(Science Applications International Corporation (United States)), Timothy Back(Science Applications International Corporation (United States)), T A Wiltrout(Science Applications International Corporation (United States)), Jong‐Wook Park(Chungbuk National University), Eilene Gruys(Frederick National Laboratory for Cancer Research), Kristin L. Komschlies(Science Applications International Corporation (United States)), Jeffrey Subleski(National Cancer Institute)
Cited by 109
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k